A pilot study to investigate the use of serum inhaled corticosteroid concentration as a potential marker of treatment adherence in severe asthma - 19/04/17
Doi : 10.1016/j.jaci.2016.08.037
Kate E. George, MRes a, b, Dorothy M. Ryan, PhD a, b, Brian Keevil, PhD a, b, Robert Niven, MD a, b, Stephen J. Fowler, MD a, b, c 
a University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom
b NIHR Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester, Manchester, United Kingdom
c Lancashire Teaching Hospitals NHS Foundation Trust, Preston, United Kingdom
| Disclosure of potential conflict of interest: All the authors declare that they have no relevant conflicts of interest. |
© 2016
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 139 - N° 3
P. 1037 - mars 2017 Retour au numéro
Article précédent
- Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site
- Karin A. van Schie, Simone Kruithof, Pauline A. van Schouwenburg, Anke Vennegoor, Joep Killestein, Gertjan Wolbink, Theo Rispens
- Hematopoietic stem cell transplantation corrects WIP deficiency
- Hamoud Al-Mousa, Abbas Hawwari, Abdulaziz Al-Ghonaium, Bandar Al-Saud, Hasan Al-Dhekri, Saleh Al-Muhsen, Sahar Elshorbagi, Majed Dasouki, Lina El-Baik, Amal Alseraihy, Mouhab Ayas, Rand Arnaout
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?